
|Articles|October 1, 2014
A Phase Ib Study of Pembrolizumab in Bladder Cancer
Author(s)Elizabeth Plimack, MD, MS
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.
Advertisement
Clinical Pearls
Elizabeth Plimack, MD, MS, director, Genitourinary Clinical Research, Fox Chase Cancer Center, discusses a phase Ib study of pembrolizumab for the treatment of patients with bladder cancer.
- 33 patients with urothelial tract cancer were enrolled on this trial.
- A subset of patients experienced a decrease in tumor volume. There were 3 complete responses.
- Overall survival data seen in this study were at the top bound of historical data.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































